Percent reduction in proptosis after teprotumumab treatment for thyroid eye disease

被引：0

作者：

Rosenblatt, Tatiana R. ^{[1
]}

Chiou, Carolina A. ^{[1
]}

Yoon, Michael K. ^{[1
]}

Lee, Nahyoung Grace ^{[1
]}

Wolkow, Natalie ^{[1
]}

Freitag, Suzanne K. ^{[1
]}

机构：

[1] Massachusetts Eye & Ear, Dept Ophthalmol, Boston, MA 02114 USA

来源：

BRITISH JOURNAL OF OPHTHALMOLOGY | 2024年

关键词：

Orbit; Inflammation; Eye Lids; Treatment Medical; Cosmesis; AGE;

D O I：

10.1136/bjo-2024-325527

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Prior studies of teprotumumab for thyroid eye disease report proptosis reduction in millimetres, which does not fully capture teprotumumab's clinical effect since a given number of millimetres change can be of variable impact depending on patients' degree of pre-treatment proptosis. In this retrospective study analysing proptosis change as a percentage of pre-treatment proptosis among 119 patients, 208 (87.4%) eyes of 110 patients had proptosis reduction averaging 14.4% (range 2.2-40.5%) of their pre-treatment proptosis, or 3.3 mm (range 0.5-10.0 mm). Reporting proptosis reduction as a percentage of pre-treatment proptosis provides a better understanding of teprotumumab's clinical impact.

引用

页数：3

共 50 条

[31] Successful Case of Teprotumumab Treatment in an Adolescent Patient With Thyroid Eye Disease
Radulovich, Nicholas
Van Brummen, Alexandra
Chambers, Christopher
Zhang, Matthew
OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2024, 40 (02): : e65 - e67
[32] Correction: Teprotumumab: A Review in Thyroid Eye Disease
Tina Nie
Yvette N. Lamb
Drugs, 2022, 82 : 1757 - 1757
[33] Improvement of asymmetric thyroid eye disease with teprotumumab
Ugradar, Shoaib
Wang, Yao
Mester, Tunde
Kahaly, George J.
Douglas, Raymond
BRITISH JOURNAL OF OPHTHALMOLOGY, 2022, 106 (06) : 755 - 759
[34] Asymmetric proptosis in thyroid eye disease
Rana, Khizar
Garg, Devanshu
Yong, Lee Shien S.
Leyden, James
Patel, Sandy
Slattery, James
Davis, Garry
Chan, Weng Onn
Selva, Dinesh
INTERNATIONAL OPHTHALMOLOGY, 2024, 44 (01)
[35] Efficacy and Safety of Teprotumumab in Thyroid Eye Disease
Teo, Honeylen Maryl
Smith, Terry J.
Joseph, Shannon S.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2021, 17 : 1219 - 1230
[36] Teprotumumab for Optic Neuropathy in Thyroid Eye Disease
Slentz, Dane H.
Smith, Terry J.
Kim, Denise S.
Joseph, Shannon S.
JAMA OPHTHALMOLOGY, 2021, 139 (02) : 244 - 247
[37] The knowns and unknowns of teprotumumab for thyroid eye disease
Bednarczuk, Tomasz
Pearce, Simon H.
LANCET DIABETES & ENDOCRINOLOGY, 2021, 9 (06): : 323 - 325
[38] Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis
Douglas, Raymond S.
EYE, 2019, 33 (02) : 183 - 190
[39] Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis
Raymond S. Douglas
Eye, 2019, 33 : 183 - 190
[40] Acquired Epiblepharon Alleviated With Teprotumumab Treatment in Active Thyroid Eye Disease Patient
Chen, Kevin W.
Phelps, Paul O.
OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2021, 37 (06): : E195 - E196

← 1 2 3 4 5 →